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A 75-year-old woman presented with tiredness, palpitations and enlargement of a longstanding 21 
goitre. Unexpectedly, thyrotropin (TSH) was not suppressed [6.3 mU/L; reference range (RR) 0.35–22 
5.5] despite markedly raised thyroid hormones [free thyroxine (FT4) 89.1 pmol/L (RR 10–19.8); free 23 
triiodothyronine (FT3) 11.7 pmol/L (RR 3.0–6.5)]. Following exclusion of laboratory assay 24 
interference, a thyrotropin-releasing hormone (TRH) test showed an attenuated response (TSH 0 25 
minutes 6.1 mU/L, 20 minutes 6.8 mU/L, 60 minutes 8.5 mU/L), raising suspicion of a 26 
thyrotropinoma (TSHoma). However, pituitary MRI was reported as normal. The patient was 27 
referred for further evaluation. On repeat MRI the pituitary gland was noted to show mild 28 
asymmetry (right>left) (figure A). Functional imaging with 11C-Methionine PET-CT (Met-PET) 29 
demonstrated intense tracer uptake (denoting active peptide synthesis) on the right side of the sella 30 
(figure A – red ‘hot spot’). Treatment with depot somatostatin analogue (SSA) led to resolution of 31 
symptoms and normalization of thyroid function (TSH 0.6 mU/L, FT4 12.5 pmol/L, FT3 3.8 pmol/L). 32 
Repeat Met-PET showed absence of the right-sided focal ‘hot spot’ (figure B). Fourteen months into 33 
treatment, the patient developed hypoglycaemic episodes, which resolved following discontinuation 34 
of SSA. However, thyrotoxicosis recurred (TSH 4.3 mU/L, FT4 38.1 pmol/L, FT3 11.6 pmol/L), and 35 
repeat Met-PET revealed reappearance of the right-sided ‘hot spot’ (figure C). At pituitary surgery a 36 
micro-TSHoma was resected from the right side of the gland (figure D). The patient remains in 37 
clinical and biochemical remission 14 months post-surgery and is eupituitary. 38 
 39 
To our knowledge, this is the first example of a microTSHoma being unmasked by functional imaging 40 
before and after endocrine manipulation (in this case SSA therapy). As MRI does not reliably detect 41 
all pituitary microadenomas (e.g. Cushing’s; microprolactinoma), we believe this novel ‘endocrine 42 
switch’ approach could find wider application in the management of such occult tumours.  43 
 44 
 45 
 46 
Contributors 47 
OK, PE and MG collected the data. All authors contributed to the writing of the report. OK, AH and 48 
MG performed the image analysis. NA and HC interpreted the imaging studies. KA reviewed the 49 
histopathology. ND & RJM performed the surgical procedure.   50 
The patient gave her written informed consent for publication of this case report. 51 
 52 
Declaration of interest 53 
OK and MG are supported by an unconditional award from Ipsen Ltd. 54 
 55 
Figure legend 56 
Figure: Imaging and histopathological findings 57 
(A) SE (Spin Echo) MRI (top panel) and 11C-methionine PET-CT co-registered with SPGR (Spoiled 58 
Gradient Recalled Acquisition) MRI (bottom panel) at presentation. Repeat imaging (B) during, and 59 
(C) following discontinuation of, SSA therapy. (D) Microscopic appearance (top panel) and positive 60 
TSH immunohistochemistry (bottom panel) of resected adenoma. 61 
A B C
Prior	to	somatostatin	analogue On	somatostatin	analogue
D
Fig. 1 Koulouri et al
Off	somatostatin	analogue
